Myocarditis as a manifestation of Erdheim–Chester Disease: successful use of anti- IL1 and BRAF inhibitor combination therapy.

The IL-1 pathway is of fundamental importance in the pathogenesis of myocardial inflammation, and its inhibition is an effective strategy for the treatment of immune-mediated myocarditis ([4]). Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis characterized by multiorgan infiltration by foamy macrophages ([1]). The temporal relationship between myocarditis onset and vemurafenib therapy introduction in our patient may suggest a role for vemurafenib in the acute myocardial inflammation. [Extracted from the article]